Uveitis

Data show ≥60% of eligible faricimab patients with DME could extend treatment to every 4 months, while 95% of ranibizumab implants in wetAMD treatment maintained a six-month schedule.

Dr. Brown discusses the most common conditions of patients treated for ocular trauma and highlights the range of performed procedures in the ED.

The study suggested children born extremely premature may remain "preterm for life," with ophthalmic sequelae persisting into adulthood.

A multitude of promising new investigative therapies are on the horizon for inherited retinal disease.

Dr. Modi discusses the pending approval of faricimab for nAMD, DME treatment and highlights important observations from phase 3 data.

Outlook Therapeutics is expected to submit a BLA to the FDA for the investigative ophthalmic bevacizumab-vikg formulation (ONS-5010).

TENAYA and LUCERNE show reduced treatment burden in nAMD patients, while vision gains and extended durability for DME patients were observed in YOSEMITE and RHINE.

Triamcinolone acetonide injectable suspension has been approved for administration via the suprachoroidal pathway—located in the back of the eye.

There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.

A submitted column on how to properly care for patients suffering from vision loss from the founder and medical director of Focus Clinics in London.

A decade of fine-tuning proven therapies and embracing advancing clinical technology has put ophthalmology in a rare space.

Katherine Talcott, MD, of Cole Eye Institute, discusses results of a 5-year study examining endogenous bacterial endophthalmitis at a tertiary care center from AAO 2019.

Aleksandra Rachitskaya, MD, of Cole Eye Institute, discusses a presentation she led at AAO 2019 on novel imaging and surgical techniques.

Louis Pasquale, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, discusses how technology and artificial intelligence has been embraced by ophthalmology.

Analysis of the FAST trial found that methotrexate performed better head-to-head than mycophenolate mofetil as a corticosteroid-sparing therapy.

Investigators presented 36-month results of a study which found that treatment with a single intravitreal injection of the FAi provided anti-inflammatory treatment for 3 years in patients with non-infectious uveitis affecting the posterior segment of the eye

Ajay Kuriyan, MD, discusses what he warns patients to be aware of when seeking out treatment from stem cell therapies and why he believes other physicians should as well.

Investigators found positive results when examining the safety and efficacy of filgotinib in the FINCH 2 phase 3 clinical trial.

Investigators found that female sex, older age, and certain comorbidities were associated with an increased risk of uveitis.

Using a national medical claims database, investigators found the incidence and prevalence of uveitis in the US.

A new phase 3 study suggests that physicians should shift away from periocular injections, and towards intravitreal injections of corticosteroids for uveitic macular edema.

Yutiq, a fluocinolone acetonide intravitreal implant, is indicated for the treatment of chronic non-infectious uveitis that affects the posterior segment of the eye.

Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.

Patients taking 440µg doses of the drug saw better results than those treated with 44µg doses

Patients experienced prolonged time to treatment failure, meeting primary endpoints in VISUAL I and II trials.

The drug, which has previously been approved to treat several other conditions, is now receiving EMA feedback for the treatment of uveitis in children.

Acute intraocular inflammation was less common for ranibizumab than aflibercept.

Uveitis recurrence was associated with failure of trabeculectomy, not implant.

Review explores reducing corticosteroid use with immunomodulatory therapies.

Despite good responses, patients dropped adalimumab treatment.